fig7

Figure 7. In vivo experiments confirmed that Fra-1 promotes GC proliferation. (A and B) Twenty 4-week-old female B/C nude mice were randomly divided into four groups: null group, Fra-1 overexpression group, null + CDDP group, and Fra-1 overexpression + CDDP group, each containing five nude mice. GC cells HGC27 overexpressing Fra-1 were inoculated into the right axilla of each mouse. Tumor size was measured every 3 days using the formula: length × width² × 0.5. When the tumor volume reached 10 mm³, CDDP solution (4 mg/kg) was injected intraperitoneally once a week. Three weeks after injection, the nude mice were euthanized, and subcutaneous tissues were collected and photographed; (C and D) Paraffin-embedded GC tumor tissues from nude mice were sectioned and subjected to immunohistochemistry experiments to detect the expression of Fra-1 and G6PD. 100×, Scale bar = 200 μm; 200×, Scale bar = 100 μm; 400×, Scale bar = 50 μm. All experiments were performed with three technical replicates. Statistical analysis was performed to determine significance levels (^**P < 0.01; ^****P < 0.0001). Fra-1: Fos-related antigen-1; GC: gastric cancer; CDDP: cisplatin; G6PD: glucose-6-phosphate dehydrogenase.